What's happening
This bill requires prescription drug manufacturers to notify the state before increasing wholesale prices by more than 10% within 24 months.
Why it matters
Shines a public spotlight on large drug price hikes. By mandating advance notice and public disclosure of significant price increases, the bill aims to increase transparency, allowing patients, insurers, and policymakers to anticipate and possibly respond to cost surges.
Encourages accountability from drug manufacturers. Requiring companies to justify price hikes, especially if claimed to be due to product improvements, could curb unjustified increases and make it harder to raise prices without scrutiny.
Strengthens consequences for non-compliance. Manufacturers who fail to report qualifying price increases face financial penalties, which could deter non-reporting and help ensure that critical pricing data is consistently available.
Protects confidential business information. While promoting transparency, the bill also safeguards manufacturers’ trade secrets, balancing public interest with proprietary concerns and potentially reducing industry pushback.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Notify State Before Drug Price Hikes
Plain English, a few words. Used as the page title.
Sponsors
10 Co-sponsors
2 Multi-sponsors
History
- Print number 663b
- Amend and recommit to health
- Print number 663a
- Amend (t) and recommit to health
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Notify State of Drug Price Hikes
In Assembly Committee · Health · Sponsor Julia Salazar
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
663--B
2021-2022 Regular Sessions
IN ASSEMBLY (Prefiled)
January 6, 2021
Introduced by M. of A. D. ROSENTHAL, DICKENS, COLTON, WILLIAMS, SEAWRIGHT, COOK, O'DONNELL, SIMON, ABINANTI, JACOBSON, GRIFFIN -- Multi-Sponsored by -- M. of A. GALEF, SALKA -- read once and referred to the Committee on Health -- recommitted to the Committee on Health in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- again reported from said committee with amendments, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The insurance law is amended by adding a new section 111-a to read as follows:
§ 111-a. Notification of prescription drug price increases by manufacturers. (a) This section shall apply to a manufacturer of a prescription drug that is purchased or reimbursed in this state by any of the following:
(1) An insurance company authorized in this state to write accident and health insurance, a company organized pursuant to article fortythree of this chapter, a municipal cooperative health benefit plan established pursuant to article forty-seven of this chapter, an organization certified pursuant to article forty-four of the public health law, an institution of higher education certified pursuant to section one thousand one hundred twenty-four of this chapter, or the New York state health insurance plan established pursuant to article eleven of the civil service law; or
(2) A pharmacy benefit manager, including an entity that directly or through an intermediary, manages the prescription drug coverage provided by a health insurer under a contract or policy delivered or issued for delivery in this state or a health plan subject to section three hundred
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05130-05-2
sixty-four-j of the social services law, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs.
(b) (1) A manufacturer of a prescription drug with a wholesale acquisition cost of more than forty dollars for a course of therapy shall notify the superintendent, his or her deputy or other officer designated by the superintendent, if the increase in the wholesale acquisition cost of such prescription drug is more than ten percent, including the proposed increase and the cumulative increases that occurred within the previous twenty-four months. For purposes of this section, a "course of therapy" is defined as either of the following:
(i) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for thirty days; or
(ii) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for a normal course of treatment that is less than thirty days.
(2) (i) The notice required by paragraph (1) of this subsection shall be provided in writing to the superintendent at least sixty days prior to the planned effective date of the increase and shall include the proposed increase and the cumulative increases that occurred within the previous twenty-four months.
(ii) The superintendent shall forthwith publish the notice required by paragraph (a) of this subdivision on the department of financial services website within five days of its receipt.
(3) (i) The notice required by paragraph (1) of this subsection shall include the date of the increase, the current wholesale acquisition cost of the prescription drug, and the dollar amount of the future increase in the wholesale acquisition cost of the prescription drug.
(ii) The notice required by paragraph (1) of this subsection shall include a statement regarding whether a change or improvement in the drug necessitates the price increase. If so, the manufacturer shall describe the change or improvement.
(4) Information supplied by a manufacturer pursuant to this section that the manufacturer has designated as a trade secret shall be considered confidential and a trade secret and shall not be disclosed directly or indirectly by the superintendent. Notwithstanding the foregoing sentence, the superintendent shall be permitted to disclose information in an aggregated format if such aggregate information cannot directly or indirectly be used to identify trade secret information related to a specific manufacturer or the manufacturer's prescription drug, including but not limited to any information related to pricing for the manufacturer's prescription drug that has been designated as a trade secret.
(5) In the event that a manufacturer of a prescription drug subject to this section does not report the information required in paragraph (1) of this subsection, the superintendent is authorized to impose any penalty or remedy authorized by this chapter, after notice and a hearing, against such manufacturer of up to five thousand dollars per day for every day after the reporting period described in this section that the required information is not reported.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.